20 mins with: Manfred Schepers, ILX Fund

Sam McManus

Director

In:

Climate finance, Renewable energy, Social projects

Region:

Middle East & Africa, Asia-Pacific

Uxolo spoke with Manfred Schepers, CEO at ILX Fund to discuss how its MDB-backed portfolio is yielding credit margin returns of 4% for its broad church of investors, and what else needs to be done to scale up development finance as an asset class. Can private creditors get extra de-risking cushions?

Exclusive subscriber content…

If you are a n Uxolo subscriber, please login to continue reading

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to Uxolo Intelligence contact us

Request Access

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating...

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the...

Life sciences: DFIs test a new frontier in health PPP

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even...

Must See

Green Sky SAF: An Egypt first with lending precedents

Perspective

04 June 2026

Green Sky SAF: An Egypt first with lending precedents

A landmark sustainable aviation fuel project in Egypt shows that commercial banks and local equity can get behind emerging transportation fuels. But shared experience on an earlier SAF financing helped assure a painless close.

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating deals, and learning to measure impact

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the development finance industry.

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even vaccine sovereignty is hard to bank without public risk-sharing, demand visibility and unusually credible developers.